Biocept expands commercial offering of cnside™ assay to most cancers that metastasize to the central nervous system

San diego--(business wire)--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products, and services, announces the expanded commercial availability of cnside for patients with metastatic melanoma.
BIOC Ratings Summary
BIOC Quant Ranking